| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue from contract with customer, including assessed tax | 1,103 | 2,777 | 3,269 | 4,351 |
| Product | 418 | 907 | - | - |
| Service | 313 | 449 | - | - |
| Cost of goods and services sold | 731 | 1,356 | 1,781 | 2,629 |
| Gross profit | 372 | 1,421 | 1,488 | 1,722 |
| Selling, general and administrative expenses | 3,088 | 2,688 | 2,559 | 2,093 |
| Research and development | 615 | 535 | 791 | 690 |
| Credit loss expense | 3,849 | - | - | - |
| Total operating expenses | 7,552 | 3,223 | 3,350 | 2,783 |
| Operating loss | -7,180 | -1,802 | -1,862 | -1,061 |
| Interest expense | 144 | - | - | - |
| Interest income | 80 | - | - | - |
| Interest expense | - | -80 | -65 | 1 |
| Ppp loan forgiveness | 0 | 0 | - | - |
| Grant income | 0 | 0 | 6 | - |
| Us-gaap_othernonoperatingincomeexpense | - | - | - | 1 |
| Total other expense | -64 | -80 | -59 | - |
| Net loss | -7,244 | -1,882 | -1,921 | -1,060 |
| Net loss attributable to noncontrolling interest | -765 | -690 | -766 | -523 |
| Net loss attributable to common shareholders | -6,479 | -1,192 | -1,155 | -537 |
| Loss per share attributable to shareholders basic and diluted (in dollars per share) | -0.02 | -0.004 | -0.004 | -0.002 |
| Weighted average number of common shares outstanding (in shares) | 308,974,027 | 303,196,989 | 301,274,243 | 300,488,824 |
BIOLARGO, INC. (BLGO)
BIOLARGO, INC. (BLGO)